Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
286 The landmark SELECT trial has demonstrated the cardiovascular benefits of the GLP-1 receptor agonist, semaglutide (2.4 mg subcutaneous once weekly), in people established atherosclerotic CVD and with a BMI 27 kg/m2 (without type 2 diabetes)
Easy dosing, with weekly application, promotes adherence to treatment and reduces the patients therapeutic burden (BAREK et al., 2024)
Additionally, many health insurance plans are beginning to cover GLP-1 medications, making them more accessible to patients
A megbzhat forrsbl szrmaz termkek kvetkezetes minsget biztosthatnak
Laboratory research record on GLP-1S [PMID: 36117924] PubMed laboratory record discussing GLP-1S in a research context
US$ 29.95
US$ 25.10
![Mechanism of action of GLP-1 [25]](https://www.researchgate.net/profile/Asfandyar-Sheikh/publication/256289222/figure/fig1/AS:614177232142337@1523442671231/Mechanism-of-action-of-GLP-1-25.png)
US$ 22.59
US$ 20.00
US$ 27.34
US$ 20.17
